Introduction
============

A recent news story in *Nature* ([@r7]) reported on a heated dispute between opposing groups of scientists in response to an alleged but uncited draft report by the European Commission (EC) on its proposed regulatory policy concerning endocrine disrupting chemicals (EDCs) ([@r11]; [@r16]). One of the participants in the dispute, Andrea Gore, a professor at the University of Texas at Austin and editor of the journal *Endocrinology,* claimed that this was "possibly the most remarkable experience in my career" and that it was "definitely more confrontational than most scientists are used to" ([@r7]). Although the details of the dispute revolve around questions about how to identify and regulate EDCs, it also highlights broader issues about how scientists should communicate with policy makers in a manner that is both policy relevant and appropriately objective. Some of the participants in the dispute called for making a sharper distinction between science and policy ([@r3]), but we argue here that society is better served when scientists strive to be as transparent as possible about the ways in which interests or values may influence their reasoning.

The conflict erupted when a group of 18 journal editors published an editorial in *Food and Chemical Toxicology* accusing the EC of preparing a regulatory system for EDCs that is "based on virtually complete ignorance of all well-established and taught principles of pharmacology and toxicology" ([@r9]). The editorial and an accompanying letter ([@r9]) focused on two issues: First, the authors of the editorial criticized the EC for proposing a system in which evidence of endocrine disruption obtained in animals and various other experimental systems would be presumed to be relevant to humans in the absence of evidence to the contrary. Second, the authors expressed the concern that the EC would presume that EDCs do not have a threshold dose below which they cease to induce adverse effects.

In response to this initial editorial, several subsequent commentaries were published ([@r3]; [@r14]; [@r15]). An editorial signed by 41 scientists and published in *Environmental Health* ([@r3]) questioned whether the EC actually envisioned a regulatory policy with the characteristics described by Dietrich and his co-authors. The editorial by [@r3] also pointed out that the International Programme on Chemical Safety (IPCS) Framework document for risk assessment ([@r17]) adopts a default assumption that evidence of toxicity in animals is relevant to humans. Moreover, the editorial argued that evidence for the existence of thresholds for EDCs, especially at the population level, remains inconclusive. Another editorial, published in the journal *Endocrinology* ([@r14]), emphasized that the assumption of no threshold for the adverse effects of EDCs is reasonable, given the evidence.

A Dispute about Science Communication
=====================================

A look beyond the scientific details of the case shows that these and other editorials ([@r3]; [@r14]; [@r15]; [@r16]; [@r21]) have raised significant issues about how scientists can appropriately inform public policy. The response in *Environmental Health* states that "\[t\]he most worrying aspect of the editorial by Dietrich et al. is the blurring of the border between what constitutes science and what belongs to the realm of political, societal and democratic choices" ([@r3]). This concern is clearly expressed in the title of the editorial: "Science and policy on endocrine disrupters must not be mixed." Related to this worry about mixing policy with science, an editorial by [@r15] suggested that a crucial flaw in the editorial by [@r9] was its failure to include a conflict-of-interest disclosure.According to Grandjean and Ozonoff, trust is necessary among scientists, editors, publishers, and members of the public, and that trust is broken when authors do not acknowledge their competing interests.

These editorials ([@r3]; [@r15]) highlight the worry that scientists are in danger of losing their objectivity when they wade into the policy domain. Because objectivity is one of science's most important goals, this concern has considerable merit. Even when scientists do not actually compromise their objectivity, people may perceive that they have done so, which can undermine the public's trust in science. Although engaging in policy-relevant research can threaten science's objectivity, a great deal would be lost if scientists refused to enter these waters because public policies should typically be informed by the best available scientific evidence ([@r30]; [@r32]). In a commentary that cites [@r9] approvingly, [@r21] argued that the Society of Toxicology (SOT) "must avoid playing it safe." In other words, they call for the members of the SOT to inform policy makers about issues on which they have expertise. However, if toxicologists and other scientists are to help inform policy, they face the question of how to do this without losing their objectivity or the public's trust.

Discussion
==========

In the past, scientists and philosophers have argued that the best way to maintain science's objectivity and the public's trust is to draw a sharp line between science and human values or policy ([@r22]). However, it is not possible to maintain this distinction, both because values are crucial for assessing what counts as sufficient evidence and because ethical, political, economic, cultural, and religious factors unavoidably affect scientific judgment ([@r10]; [@r13]; [@r22]; [@r31], [@r32]). Insisting that science is value-free, when the arguments and evidence show that this is an unrealistic goal, perpetuates a misunderstanding that interferes with the public's understanding of the scientific process and may, paradoxically, undermine the public's trust in science. We suggest that society is likely to be better served when scientists strive to be as transparent as possible about the ways that interests and values may influence their judgment and reasoning, while still striving for objectivity. Transparency can promote public trust by helping laypeople understand how both empirical evidence and value assumptions enter into scientific decision making and policy formation. As the National Research Council (NRC) report *Understanding Risk* ([@r28]) emphasized, it is usually unrealistic to keep the process of risk characterization purely value-free. Instead, the report called for incorporating broad-based deliberation about the values that inform risk assessments in order to provide a context for the scientific analyses that are part of the assessment process.

*Standards of evidence*. The first reason it is problematic to draw a sharp separation between science and values is that values are necessary to decide what standards of evidence to demand when informing policy decisions ([@r1]; [@r4]; [@r10]; [@r13]). Several comments from the recent dispute about the proposed EC policy illustrate the difficulties of trying to ignore this necessary role for values. First, as noted earlier, the editorial that calls for science and policy on EDCs to remain "unmixed" ([@r3]) insists that it is reasonable to assume that evidence of toxicity in animals is relevant to humans. The authors argue that the alternative assumption (i.e., that effects in animals do not provide evidence for effects in humans) "would be unworkable" ([@r3]). But this conclusion incorporates value judgments concerning the standards of evidence that are appropriate for regulating chemicals. Insisting that chemicals should be regulated only in response to evidence from human studies would help to prevent false positive conclusions about chemical toxicity, but it would also prevent society from taking effective action to minimize the risks of chemicals before they produce measurable adverse effects in humans. Moreover, insisting on human studies would result in failure to identify some human health risks because the diseases are rare, or the induction and latency periods are long, or the effects are subtle ([@r6]).

Similarly, [@r14] argued that "\[t\]he assumption of no threshold has been widely used, for many years, in the regulation of genotoxic carcinogens, often based upon in vitro data. We believe extending this precedent to EDCs is supported by the science." But the claim that the no-threshold hypothesis is "supported by the science" depends on implicit assumptions about how much scientific evidence is needed to justify formulating policy on this basis. And the question of how much evidence is needed should depend in part on value judgments about the relative benefits and harms to society of assuming (or not assuming) a threshold when performing risk assessments of EDCs. In this case, past toxicological experience may support the threshold hypothesis, whereas other lines of evidence (such as the proposed molecular mechanisms by which EDCs could disrupt development and generate irreversible effects on endocrine-sensitive organs) support the no-threshold hypothesis. Thus, the dispute between [@r14] and [@r9] regarding the adoption of thresholds for EDCs could be clarified if the participants were more forthcoming about their assumptions regarding the level and kind of evidence needed to justify adopting or rejecting the threshold hypothesis.

In their editorial, [@r21] call for the members of the SOT to be "strong advocates for applying the best science" to policy issues and to craft regulatory policies that are "based on sound science." Even this seemingly innocuous advice to promote decisions based on good science hides significant value judgments about the appropriate standards of evidence in policy contexts ([@r1]; [@r4]). If the "best science" and "sound science" are interpreted to mean science that meets the highest standards of scientific evidence, then it is not clear that regulatory policy must always be based on this form of evidence, because it may be appropriate to use different standards of evidence to protect the public from risks. A continuum of different kinds and amounts of evidence could be demanded for policy decisions ([@r1]). Very high standards of evidence are typically expected in order to infer causal relationships or to approve the marketing of new drugs. In other social contexts, such as tort law and chemical regulation, weaker standards of evidence are sometimes acceptable to protect the public ([@r5]). To demand the very highest standards of evidence for chemical regulation---including, for example, human evidence, accompanying animal data, mechanistic evidence, and clear exposure data---would take very long periods of time and leave the public's health at risk. Thus, the demand that regulators rely on the same standards of evidence for toxicity as the scientific community uses in other contexts is itself a value-laden proposal.

The value-laden assumptions about standards of evidence in this dispute over endocrine disruption are similar to broader social disputes over the precautionary principle ([@r20]; [@r23]; [@r27]; [@r35]). Indeed, the title of the editorial by [@r9] begins with the claim, "Scientifically unfounded precaution drives European Commission's recommendations on EDC regulation." Some critics of the precautionary principle, such as Dietrich and his coauthors, argue that precaution runs counter to scientific principles ([@r27]). But decisions about how much evidence to demand before taking regulatory actions necessarily incorporate both scientific judgments and value judgments. Because the scientific conventions for inferring evidence of harm in some fields might require placing the public at risk for extended periods of time before the evidence could be accumulated, precautionary decisions to engage in particular forms of regulation may sometimes be appropriate in response to more limited evidence ([@r6]; [@r23]).

*Financial, personal, and cultural influences*. A second reason to avoid trying to maintain a sharp distinction between science and values in the policy context is that personal, ethical, political, and cultural values unavoidably influence scientific reasoning. This point is illustrated by recent conceptual and empirical literature on the ways that financial relationships can affect scientific judgment and reasoning ([@r8]; [@r12]; [@r33]). An investigative report found that 17 of the 18 authors of the initial editorial by [@r9] had ties to regulated industries ([@r16]). In response to this investigation, Dietrich replied, "\[w\]e do not believe the discussion on the conflicts of interests will serve anybody because it takes away the focus from the real issue" (quoted by [@r16]). Bas Blaauboer, another co-author of the editorial by [@r9], insisted that it was "very stupid" to think that his industry involvement influenced his opinion (quoted by [@r16]). But psychological studies have suggested that financial interests can exert subconscious influences on human judgment even when individuals are instructed about those potential influences and motivated to remain objective ([@r2]; [@r8]; [@r29]). Importantly, people typically underestimate the strength of these influences ([@r8]; [@r19]). Some commentators also worry that interest groups with "deep pockets" can use their financial and political power to skew public debate by magnifying the influence of sympathetic scientists through strategic funding efforts and public relations campaigns ([@r24]; [@r26]).

Financial relationships are not the only factors that can influence scientists. Studies of risk perception have found that even among professional toxicologists, men tend to have systematically lower perceptions of chemical risks than women, and those employed by industry have lower perceptions of risk than those in academic settings ([@r34]). Some of these employment effects may be caused or exacerbated by the phenomenon of group polarization, whereby people exposed primarily to those who share similar views ultimately adopt more extreme positions (e.g., [@r35]). Even cultural values---concerns about equality, authority, individualism, and community---can influence individuals' risk perceptions ([@r18]). This evidence from the social sciences suggests that although scientists can strive for objectivity, it is unrealistic to think that they can provide policy advice without being influenced by a variety of subconscious factors, such as interests and values.

Conclusions
===========

Given both that values play a crucial role in choosing standards of evidence in the policy context and that values have subconscious influences on scientific judgment that are impossible to eliminate completely, we suggest that the best way to do policy-relevant research is for scientists to be as transparent as possible about the ways in which interests and values may influence their work ([@r1]). The analytic--deliberative approach to risk characterization described in *Understanding Risk* ([@r28]) provides one model for promoting this sort of transparency, but a number of other strategies for promoting transparency are also available. For example, efforts to incorporate scientists from a range of different stakeholder groups on government advisory bodies can help to uncover and elucidate implicit value judgments in science advice and promote democratic decision making ([@r32]). These efforts to uncover implicit value judgments are important, given that values can influence subtle decisions about research questions, methodologies, terminology, and models ([@r1]; [@r10]; [@r13]; [@r20]). Disclosures of competing financial interests and nonfinancial interests (such as professional or political allegiances) also provide opportunities for more transparent discussions of the impact of potentially implicit and subconscious values ([@r33]).

When scientists are aware of important background assumptions or values that inform their work, it is valuable for them to make these considerations explicit. They can also make their data publicly available and strive to acknowledge the range of plausible interpretations of available scientific information, the limitations of their own conclusions, the prevalence of various interpretations across the scientific community, and the policy options supported by these different interpretations. This approach has much in common with Ashford's seminal call for scientists to be transparent about their values ([@r1]) and with Pielke's vision of scientists as "honest brokers" who open up discussions about the range of options available to decision makers ([@r30]). It may even be valuable for scientists to reflect on how their work fits into broader social frames or narratives so that they can anticipate how their claims are likely to be misinterpreted or used to promote particular political or economic agendas ([@r25]).

Although scientists are rightly taught to strive for objectivity, efforts to maintain a sharp distinction between science and policy are likely to be counterproductive in such cases as the recent dispute over EDCs. When scientific evidence is disputed and major regulatory decisions are at stake, it is unrealistic to think that scientists will not be influenced by their financial, social, political, and personal interests or values when they offer advice to policy makers. Moreover, judgments about whether EDCs exhibit thresholds or whether an alleged EDC will have adverse effects in humans rest not only on scientific evidence but also on value-laden judgments about the appropriate standards of evidence. Even calls for decisions "based on sound science" incorporate implicit value judgments about the appropriate standards of evidence for drawing policy-relevant conclusions. In cases such as these, efforts to suppress or hide interests or values may actually damage scientific objectivity and public trust, whereas a willingness to bring implicit interests or values into the open may be the best path to promoting good science and policy.
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